Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687632 · ClinicalTrials.gov registry record · Phase 2
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03687632: Completed Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
NCT03687632 is a Phase 2 study that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03687632, a Phase 2 study, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
Primary Outcome
Healing is defined as the complete re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
Interventions
- BIOLOGICAL ST266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 2 |
What the finished NCT03687632 record still lists
NCT03687632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which ST266 is the first listed.
NCT03687632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03687632 about?
NCT03687632 is a clinical study titled "ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects". The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
What is the current status of trial NCT03687632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-06-10. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT03687632?
The interventions under investigation include: ST266 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03687632?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03687632's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI